CY1113171T1 - Αντιφλεγμονωδεις παραγοντες - Google Patents
Αντιφλεγμονωδεις παραγοντεςInfo
- Publication number
- CY1113171T1 CY1113171T1 CY20121100921T CY121100921T CY1113171T1 CY 1113171 T1 CY1113171 T1 CY 1113171T1 CY 20121100921 T CY20121100921 T CY 20121100921T CY 121100921 T CY121100921 T CY 121100921T CY 1113171 T1 CY1113171 T1 CY 1113171T1
- Authority
- CY
- Cyprus
- Prior art keywords
- inflammating
- factors
- medicament
- prevention
- manufacture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η εφεύρεση αναφέρεται στη χρησιμοποίηση παραγώγων 3-αμινοκαπρολακτάμης για την παρασκευή ενός φαρμάκου με σκοπό την πρόληψη ή θεραπεία φλεγμονωδών διαταραχών, και χρησιμοποιεί ενώσεις του γενικού τύπου (I) ή φαρμακευτικώς αποδεκτά άλατα αυτών· όπου το Χ είναι -CO-R1 ή -SO2-R2, και τα R1 και R2 είναι ανθρακούχοι υποκατάστατες.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0327775A GB0327775D0 (en) | 2003-12-01 | 2003-12-01 | Anti-inflammatory agents |
GB0417436A GB0417436D0 (en) | 2004-08-05 | 2004-08-05 | Anti-inflammatory agents |
GB0417734A GB0417734D0 (en) | 2004-08-10 | 2004-08-10 | Anti-Inflammatory agents |
EP04798708A EP1691814B9 (en) | 2003-12-01 | 2004-11-30 | Anti-inflammatory agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113171T1 true CY1113171T1 (el) | 2016-04-13 |
Family
ID=34657584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100921T CY1113171T1 (el) | 2003-12-01 | 2012-10-04 | Αντιφλεγμονωδεις παραγοντες |
Country Status (17)
Country | Link |
---|---|
US (1) | US20080227724A1 (el) |
EP (2) | EP1691814B9 (el) |
JP (1) | JP5248779B2 (el) |
KR (1) | KR101228268B1 (el) |
CN (1) | CN103393691A (el) |
AR (1) | AR047730A1 (el) |
CA (1) | CA2547651C (el) |
CY (1) | CY1113171T1 (el) |
DK (1) | DK1691814T3 (el) |
ES (1) | ES2390272T3 (el) |
HK (1) | HK1094680A1 (el) |
IL (1) | IL175857A0 (el) |
PL (1) | PL1691814T3 (el) |
PT (1) | PT1691814E (el) |
SI (1) | SI1691814T1 (el) |
TW (1) | TWI356821B (el) |
WO (1) | WO2005053702A2 (el) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2418426A (en) | 2004-08-18 | 2006-03-29 | Univ Cambridge Tech | Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders |
AU2011226837B2 (en) * | 2004-09-02 | 2014-09-18 | Cambridge Enterprise Limited | Ligands for G-protein coupled receptors |
GB2418427A (en) * | 2004-09-02 | 2006-03-29 | Univ Cambridge Tech | Ligands for G-protein coupled receptors |
GB0512238D0 (en) * | 2005-06-15 | 2005-07-27 | Univ Cambridge Tech | Anti-inflammatory agents |
US7662967B2 (en) | 2007-08-02 | 2010-02-16 | Cambridge Enterprise Limited | Anti-inflammatory compounds and compositions |
GB2452696B (en) | 2007-08-02 | 2009-09-23 | Cambridge Entpr Ltd | 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions |
GB2455539B (en) * | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
GB201009603D0 (en) | 2010-06-08 | 2010-07-21 | Cambridge Entpr Ltd | Anti-inflammatory agent |
US9340483B2 (en) * | 2012-02-15 | 2016-05-17 | Anida Pharma Inc. | Methods of treating amyotrophic lateral sclerosis |
JP2020505385A (ja) * | 2017-01-18 | 2020-02-20 | ウニヴェルジテート オートノマ デ バルセロナ | 神経変性疾患及び/又は自己免疫性疾患の処置において使用するための抗炎症性脂質メディエーター |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB327775A (en) | 1929-01-21 | 1930-04-17 | John Harry Grayson | Improvements in thermostats |
BE402700A (el) | 1933-06-02 | |||
US3786093A (en) * | 1969-10-17 | 1974-01-15 | Allied Chem | Novel bisamides containing fluorine |
JPS53121781A (en) * | 1977-03-30 | 1978-10-24 | Torii Yakuhin Kk | Caprolactum derivatives |
JPS625994A (ja) * | 1985-07-02 | 1987-01-12 | Toray Ind Inc | リジン誘導体の製造法 |
EP0312157A3 (en) * | 1987-10-13 | 1990-07-25 | Merck & Co. Inc. | Tetrapeptide renin inhibitors having a novel c-terminal amino acid |
JP3054738B2 (ja) * | 1988-07-22 | 2000-06-19 | 武田薬品工業株式会社 | チアゾロ[5,4―b]アゼピン誘導体 |
DK316989D0 (da) | 1989-06-26 | 1989-06-26 | Novo Nordisk As | Enzymer |
US5430022A (en) * | 1990-05-14 | 1995-07-04 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compound and its preparation |
IT1247698B (it) * | 1990-06-21 | 1994-12-30 | Sigma Tau Ind Farmaceuti | 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
IT1254471B (it) * | 1992-02-27 | 1995-09-25 | Magis Farmaceutici | Derivati ammidici della (r)-glicerofosforil-(s)-serina o del suo diacil derivato, un processo per la loro preparazione e relative composizioni farmaceutiche per il potenziamento dei processi di apprendimento |
US5821231A (en) * | 1993-12-06 | 1998-10-13 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using same |
EA002348B1 (ru) * | 1995-02-22 | 2002-04-25 | Новартис Аг | Соединения 1-арил-2-ациламиноэтана и их применение в качестве антагонистов нейрокинина, в частности нейрокинина 1 |
SG64939A1 (en) * | 1995-07-17 | 2002-02-19 | Mitsui Chemicals Inc | Olefin polymerization catalyst, process for preparing olefin polymer, and olefin polymer |
JP3633060B2 (ja) | 1995-09-22 | 2005-03-30 | Jsr株式会社 | 低結晶性エチレン系ランダム共重合体およびその組成物 |
US5817757A (en) * | 1995-10-30 | 1998-10-06 | Merck & Co., Inc. | Inhibitors of peptide binding to MHO class II proteins |
ATE377006T1 (de) * | 1995-11-28 | 2007-11-15 | Cephalon Inc | Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer |
MY132550A (en) * | 1996-08-22 | 2007-10-31 | Novartis Ag | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists |
GB9621836D0 (en) * | 1996-10-19 | 1996-12-11 | Zeneca Ltd | Peptide compounds |
EA002100B1 (ru) * | 1996-12-23 | 2001-12-24 | Элан Фармасьютикалз, Инк. | ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ |
US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US6506782B1 (en) * | 1998-02-27 | 2003-01-14 | Athena Neurosciences, Inc. | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
KR20010012773A (ko) * | 1998-03-20 | 2001-02-26 | 도리이 신이치로 | 페닐메틸 벤조퀴논을 유효성분으로 함유하는 NF-κB억제제 |
US6395282B1 (en) | 1998-04-16 | 2002-05-28 | University Of Rochester | Immunogenic conjugates of Gram-negative bacterial autoinducer molecules |
HRP990246A2 (en) * | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
US6117870A (en) * | 1998-11-12 | 2000-09-12 | Fujirebio Kabushiki Kaisha | Cyclic amide derivatives |
EP1141011A2 (en) | 1999-01-12 | 2001-10-10 | Neorx Corporation | Compounds and methods to inhibit or augment an inflammatory response |
US6344450B1 (en) * | 1999-02-09 | 2002-02-05 | Bristol-Myers Squibb Company | Lactam compounds and their use as inhibitors of serine proteases and method |
AU2001243601A1 (en) * | 2000-03-10 | 2001-09-24 | Ariad Pharmaceuticals, Inc. | Caprolactam derivatives and uses thereof |
-
2004
- 2004-11-30 JP JP2006542002A patent/JP5248779B2/ja active Active
- 2004-11-30 US US10/581,274 patent/US20080227724A1/en not_active Abandoned
- 2004-11-30 EP EP04798708A patent/EP1691814B9/en not_active Not-in-force
- 2004-11-30 SI SI200431939T patent/SI1691814T1/sl unknown
- 2004-11-30 PT PT04798708T patent/PT1691814E/pt unknown
- 2004-11-30 TW TW093136880A patent/TWI356821B/zh not_active IP Right Cessation
- 2004-11-30 DK DK04798708.6T patent/DK1691814T3/da active
- 2004-11-30 KR KR1020067010733A patent/KR101228268B1/ko not_active IP Right Cessation
- 2004-11-30 EP EP10011516A patent/EP2279741A3/en not_active Withdrawn
- 2004-11-30 CA CA2547651A patent/CA2547651C/en not_active Expired - Fee Related
- 2004-11-30 CN CN2013103149649A patent/CN103393691A/zh active Pending
- 2004-11-30 WO PCT/GB2004/005030 patent/WO2005053702A2/en active Application Filing
- 2004-11-30 ES ES04798708T patent/ES2390272T3/es active Active
- 2004-11-30 PL PL04798708T patent/PL1691814T3/pl unknown
- 2004-12-01 AR ARP040104477A patent/AR047730A1/es not_active Application Discontinuation
-
2006
- 2006-05-23 IL IL175857A patent/IL175857A0/en unknown
-
2007
- 2007-02-21 HK HK07101966.1A patent/HK1094680A1/xx not_active IP Right Cessation
-
2012
- 2012-10-04 CY CY20121100921T patent/CY1113171T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP5248779B2 (ja) | 2013-07-31 |
TW200526585A (en) | 2005-08-16 |
EP2279741A2 (en) | 2011-02-02 |
US20080227724A1 (en) | 2008-09-18 |
CN103393691A (zh) | 2013-11-20 |
EP1691814B1 (en) | 2012-07-25 |
IL175857A0 (en) | 2008-02-09 |
CA2547651C (en) | 2015-06-23 |
WO2005053702A3 (en) | 2005-09-15 |
DK1691814T3 (da) | 2012-10-29 |
PT1691814E (pt) | 2012-10-16 |
EP1691814A2 (en) | 2006-08-23 |
KR101228268B1 (ko) | 2013-01-31 |
KR20070018807A (ko) | 2007-02-14 |
AR047730A1 (es) | 2006-02-15 |
SI1691814T1 (sl) | 2012-11-30 |
HK1094680A1 (en) | 2007-04-04 |
EP2279741A3 (en) | 2011-06-01 |
CA2547651A1 (en) | 2005-06-16 |
EP1691814B9 (en) | 2013-02-20 |
PL1691814T3 (pl) | 2012-12-31 |
WO2005053702A2 (en) | 2005-06-16 |
JP2007512387A (ja) | 2007-05-17 |
ES2390272T3 (es) | 2012-11-08 |
TWI356821B (en) | 2012-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113171T1 (el) | Αντιφλεγμονωδεις παραγοντες | |
CY1122863T1 (el) | Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα | |
CY1110247T1 (el) | Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων | |
CY1109656T1 (el) | Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης | |
CY1105441T1 (el) | Ετepοκυκλικοι σουλφοναμιδικοι αναστολεις της παραγωγης βητα αμυλοειδους | |
CY1115227T1 (el) | Νεοι καταστολεις φωσφοδιεστερασης (phosphodiesterase) | |
CY1108183T1 (el) | Θειαζολυλο-διυδρο-ινδαζολια | |
CY1120081T1 (el) | Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90 | |
CY1111425T1 (el) | ΠΑΡΑΓΩΓΑ ΤΗΣ ΠΥΡΙΔΟ[2,1-a]-ΙΣΟΚΙΝΟΛΙΝΗΣ ΩΣ DPP-IV ΑΝΑΣΤΟΛΕΙΣ | |
CY1105621T1 (el) | Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους | |
CY1110419T1 (el) | Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ | |
CY1115533T1 (el) | Παραγωγα χολικου οξεος ως προσδετες fxr για την προληψη ή τη θεραπευτικη αγωγη νοσηματων ή καταστασεων οι οποιες προκαλουνται με τη μεσολαβηση fxr | |
CY1110580T1 (el) | Νεα παραγωγα βενζοϊμιδαζολιου χρησιμα ως αντιπολλαπλασιαστικοι παραγοντες | |
CY1106674T1 (el) | Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους | |
HUP0400206A2 (hu) | Metalloproteináz inhibitor hatású imidazolidin-dion-származékok, ezek alkalmazása gyógyszerkészítmények előállítására és ezeket tartalmazó gyógyszerkészítmények | |
CY1117221T1 (el) | Παραγωγα αζα σπειρο αλκανιου ως αναστολεις μεταλλοπρωτεασων | |
CY1113766T1 (el) | Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων | |
CY1112232T1 (el) | Κινολινικα παραγωγα ως αναστολεις φωσφοδιεστερασης | |
CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
CY1109348T1 (el) | Διυδρο-θειενο-πυριμιδινες για τη θεραπεια φλεγμονωδων παθησεων | |
CY1110863T1 (el) | Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα | |
MX2007000505A (es) | Derivados de oxindol sustituidos y medicamentos que contienen los mismos. | |
CY1111876T1 (el) | Νεες πυρρολες με υπολiπiδaiμiκες και υποχοληστερολαιμικες δραστικοτητες, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τις περιεχουν και η χρηση αυτων στην ιατρικη | |
CY1105784T1 (el) | Εκδοχα της πιπepαζινυλακυλπιπepιδινης η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη | |
CY1106645T1 (el) | Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος |